Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Current Leases (2016 - 2025)

Historic Current Leases for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $441000.0.

  • Zevra Therapeutics' Current Leases fell 1833.33% to $441000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $441000.0, marking a year-over-year decrease of 1833.33%. This contributed to the annual value of $420000.0 for FY2024, which is 2265.19% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Current Leases stood at $441000.0, which was down 1833.33% from $525000.0 recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Current Leases peaked at $596000.0 during Q2 2024, and registered a low of $336000.0 during Q1 2021.
  • In the last 5 years, Zevra Therapeutics' Current Leases had a median value of $463000.0 in 2023 and averaged $460500.0.
  • Its Current Leases has fluctuated over the past 5 years, first skyrocketed by 3581.66% in 2022, then tumbled by 2265.19% in 2024.
  • Zevra Therapeutics' Current Leases (Quarter) stood at $356000.0 in 2021, then skyrocketed by 34.83% to $480000.0 in 2022, then grew by 13.12% to $543000.0 in 2023, then dropped by 22.65% to $420000.0 in 2024, then rose by 5.0% to $441000.0 in 2025.
  • Its Current Leases stands at $441000.0 for Q3 2025, versus $525000.0 for Q2 2025 and $589000.0 for Q1 2025.